Endo Pharmaceuticals Holdings (ENDP) Tops Q3 EPS by 2c; Adjusts FY12 Outlook
Tweet
Share
E-mailGet Alerts ENDP Hot Sheet
Join SI Premium – FREE
Endo Pharmaceuticals Holdings (NASDAQ: ENDP) reported Q3 EPS of $1.28, $0.02 better than the analyst estimate of $1.26. Revenue for the quarter came in at $750 million versus the consensus estimate of $788.53 million.
Sees FY2012 EPS of $5.00-$5.10, versus the consensus of $5.03. Endo Pharmaceuticals Holdings sees FY2012 revenue of $3.05 billion, versus the consensus of $3.10 billion.
For earnings history and earnings-related data on Endo Pharmaceuticals Holdings (ENDP) click here.
Sees FY2012 EPS of $5.00-$5.10, versus the consensus of $5.03. Endo Pharmaceuticals Holdings sees FY2012 revenue of $3.05 billion, versus the consensus of $3.10 billion.
For earnings history and earnings-related data on Endo Pharmaceuticals Holdings (ENDP) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
- Blackhawk Network (HAWK) Reports Q2 Loss of $0.07; Offers Guidance
- SanDisk upgraded at JPMorgan after investor day; shares climb
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
